Krabbe Disease

Overview

Plain-Language Overview

Krabbe Disease is a rare inherited disorder that affects the nervous system, specifically the brain and spinal cord. It is caused by a deficiency of an important enzyme that helps break down certain fats called galactolipids. Without this enzyme, harmful substances build up and damage the protective covering of nerve cells called myelin, leading to severe problems with movement and development. Symptoms often begin in infancy and include muscle stiffness, feeding difficulties, and developmental delays. The disease progressively worsens, affecting a child's ability to move, see, and hear, and can be life-threatening.

Clinical Definition

Krabbe Disease is a lysosomal storage disorder caused by a deficiency of the enzyme galactocerebrosidase (GALC) due to mutations in the GALC gene. This deficiency leads to accumulation of toxic metabolites such as psychosine, which causes widespread demyelination in the central and peripheral nervous systems. The disease primarily affects oligodendrocytes and Schwann cells, resulting in progressive neurological decline. It typically presents in infancy with symptoms including spasticity, irritability, and developmental regression, but late-onset forms also exist. The condition is autosomal recessive and is associated with rapid neurodegeneration and early mortality if untreated.

Inciting Event

There is no external trigger; disease onset is due to inherited GALC enzyme deficiency.
Symptom onset typically follows the accumulation of psychosine reaching toxic levels in the nervous system.

Latency Period

Symptoms usually appear within the first 3 to 6 months of life in the infantile form.
Late-onset forms may have a variable latency period ranging from childhood to adulthood.

Diagnostic Delay

Early symptoms such as irritability and feeding difficulties are nonspecific and often misattributed to common infant conditions.
Lack of awareness of Krabbe disease leads to delayed consideration in differential diagnosis.
Initial neuroimaging findings may be subtle and mistaken for other leukodystrophies or metabolic disorders.

Clinical Presentation

Signs & Symptoms

Irritability and feeding difficulties in infants
Progressive spasticity and stiffness
Developmental regression with loss of previously acquired skills
Seizures and abnormal movements
Visual impairment due to optic nerve involvement

History of Present Illness

Progressive irritability, spasticity, and developmental regression are hallmark early symptoms.
Affected infants develop hypertonia, seizures, and feeding difficulties over weeks to months.
Late-stage disease includes blindness, deafness, and severe neurodegeneration leading to death usually by 2 years of age.

Past Medical History

Typically unremarkable unless there is a history of previous sibling with Krabbe disease.
No prior infections or exposures are causative but may complicate clinical course.

Family History

Positive family history of early infant death or neurodegenerative disease suggests autosomal recessive inheritance.
Siblings may be affected or identified as asymptomatic carriers through genetic testing.
Consanguineous parents increase the likelihood of affected offspring.

Physical Exam Findings

Hypertonia with spasticity and increased deep tendon reflexes
Developmental delay and regression of motor milestones
Optic atrophy leading to visual impairment
Seizures in advanced stages
Peripheral neuropathy signs such as decreased muscle bulk and weakness

Diagnostic Workup

Diagnostic Criteria

Diagnosis of Krabbe Disease is established by demonstrating markedly reduced galactocerebrosidase enzyme activity in leukocytes or fibroblasts. Genetic testing confirming pathogenic mutations in the GALC gene provides definitive diagnosis. Neuroimaging with brain MRI typically shows characteristic white matter abnormalities consistent with demyelination. Elevated levels of psychosine in dried blood spots can serve as a sensitive biochemical marker. Newborn screening programs often include enzyme assay for early detection.

Pathophysiology

Key Mechanisms

Deficiency of galactocerebrosidase (GALC) enzyme leads to accumulation of toxic metabolites such as psychosine in the nervous system.
Psychosine accumulation causes oligodendrocyte and Schwann cell death, resulting in widespread demyelination of central and peripheral nerves.
Neuroinflammation and gliosis contribute to progressive neurodegeneration and white matter damage.
Impaired myelin maintenance disrupts nerve conduction, leading to neurological deficits.

Involvement	Details
Organs	Brain involvement leads to progressive neurodegeneration, developmental delay, and spasticity.
Organs	Peripheral nervous system damage causes weakness and sensory deficits.
Tissues	White matter of the central nervous system is severely affected due to widespread demyelination.
Tissues	Peripheral nerves also undergo demyelination, contributing to peripheral neuropathy symptoms.
Cells	Oligodendrocytes are the primary cells affected in Krabbe disease, undergoing apoptosis due to toxic accumulation of psychosine.
Cells	Macrophages accumulate globoid cells in the white matter, contributing to demyelination and neuroinflammation.
Chemical Mediators	Psychosine accumulates due to deficient galactocerebrosidase activity and is directly toxic to myelin-producing cells.
Chemical Mediators	Galactocerebrosidase enzyme deficiency caused by mutations in the GALC gene is the primary biochemical defect.

Treatments

Pharmacological Treatments

Non-pharmacological Treatments

Hematopoietic stem cell transplantation is used early in the disease course to provide a source of functional galactocerebrosidase enzyme and slow disease progression.
Supportive care includes physical therapy to manage spasticity and maintain mobility.
Nutritional support and respiratory care are essential to manage complications and improve quality of life.

Prevention

Pharmacological Prevention

No established pharmacological prevention exists for Krabbe disease
Hematopoietic stem cell transplantation (HSCT) may slow progression if done pre-symptomatically
Experimental enzyme replacement therapies are under investigation
Genetic counseling and prenatal testing can guide family planning

Non-pharmacological Prevention

Newborn screening programs enable early diagnosis and intervention
Genetic counseling for families with known GALC mutations
Early HSCT referral before symptom onset improves outcomes
Supportive care including physical therapy to maintain function
Avoidance of infections and aspiration through careful feeding techniques

Outcome & Complications

Complications

Progressive neurodegeneration leading to severe disability
Respiratory failure from aspiration pneumonia
Seizure-related injuries
Contractures and joint deformities from spasticity
Early death typically within the first two years of life in infantile form

Short-term Sequelae	Long-term Sequelae
Rapid developmental regression within months of symptom onset Feeding difficulties leading to weight loss Increased muscle tone causing discomfort and irritability Seizure onset worsening neurological status Visual deterioration impairing interaction	Severe intellectual disability and loss of voluntary motor function Permanent spasticity and paralysis Blindness from optic atrophy Chronic respiratory insufficiency requiring supportive care Early mortality due to progressive CNS and systemic involvement

Differential Diagnoses

Krabbe Disease versus Metachromatic Leukodystrophy

Krabbe Disease	Metachromatic Leukodystrophy
Autosomal recessive inheritance due to GALC gene mutations	Autosomal recessive inheritance due to ARSA gene mutations
Deficiency of galactocerebrosidase enzyme activity	Deficiency of arylsulfatase A enzyme activity
Diffuse white matter demyelination including U-fibers with early involvement of corticospinal tracts	Symmetric periventricular white matter demyelination sparing U-fibers
Infantile onset typically before 6 months	Late infantile to juvenile onset (1-5 years)

Krabbe Disease versus Adrenoleukodystrophy

Krabbe Disease	Adrenoleukodystrophy
Autosomal recessive inheritance affecting both sexes equally	X-linked recessive inheritance affecting males
Normal VLCFAs with elevated psychosine levels	Elevated plasma very long chain fatty acids (VLCFAs)
Diffuse cerebral white matter involvement including corticospinal tracts	Posterior cerebral white matter and splenium involvement on MRI
Rapid neurodegeneration without primary adrenal involvement	Progressive neurologic decline with adrenal insufficiency

Krabbe Disease versus Canavan Disease

Krabbe Disease	Canavan Disease
Autosomal recessive due to GALC gene mutations	Autosomal recessive due to ASPA gene mutations
Elevated psychosine with normal NAA levels	Elevated N-acetylaspartic acid (NAA) in urine and brain
Diffuse demyelination with globoid cells and no NAA elevation	Diffuse symmetric spongiform degeneration of white matter with increased NAA peak on MR spectroscopy
Infantile onset with irritability and spasticity	Early infancy with hypotonia and macrocephaly

Krabbe Disease versus Pelizaeus-Merzbacher Disease

Krabbe Disease	Pelizaeus-Merzbacher Disease
Autosomal recessive due to GALC gene mutations	X-linked recessive due to PLP1 gene mutations
Demyelination with globoid cell infiltration	Diffuse hypomyelination with lack of normal myelin development on MRI
Infantile onset with irritability and spasticity	Neonatal or early infancy with nystagmus and hypotonia
Rapidly progressive neurodegeneration	Chronic progressive with variable severity